

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/036222 A1(51) International Patent Classification?: G01N 33/569,
A61K 39/395, C07K 16/14(21) International Application Number:
PCT/SE2003/001638

(22) International Filing Date: 21 October 2003 (21.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203116-9 21 October 2002 (21.10.2002) SE

(71) Applicant and

(72) Inventor: MATTSBY-BALTZER, Inger [SE/SE];
Förtroligheten 23, S-412 70 Göteborg (SE).


(72) Inventor; and

(75) Inventor/Applicant (for US only): KONDORI, Nahid
[SE/SE]; Smedsbacken 9, S-431 39 Mölndal (SE).(74) Agent: AWAPATENT AB; Box 11394, S-404 28 Göte-
borg (SE).(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ (utility model), CZ, DE (utility model), DE, DK (utility
model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI
(utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: ANTIBODIES REACTIVE WITH β (1-3) -GLUCANS

(57) Abstract: Monoclonal antibodies reactive with β (1-3) -glucans are disclosed. More precisely, two monoclonal antibodies, B3B and A10A, reactive with β (1-3) -glucan and/or β (1-3) (1-6) -glucan associated epitopes in free, non-associated form, and/or in cell wall fragments of *Candida* and *Cryptococcus* is disclosed. Further, A10A is also reactive with a β (1-6) (1-3) -glucan epitope present on the intact cell surface of *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and/or *C. neoformans*. Said antibodies can be used for the detection of free, cell wall associated, and/or cell surface associated β (1-3) glucans utilizing immunoassays or immunohistology for the laboratory diagnosis of fungal infections. They may be used also for detection of airborne mould, or mould present in dust, water, or in any other component.

WO 2004/036222 A1



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ANTIBODIES REACTIVE WITH $\beta(1-3)$ -GLUCANSTechnical field

The present invention relates to new antibodies re-active with $\beta(1-3)$ -glucans, as well as to the use of such antibodies.

5

Background of the invention

Fungal infections may occur at many places in the human or animal body, e.g. in the vagina or in the oral cavity.

10 Invasive fungal infections are increasing because of the growing number of immunocompromised patients (7). Almost all of these infections occur in critically ill patients suffering from an underlying disease.

15 In *Candida* species which are the most common fungi isolated from patients with invasive fungal infection, the yeast cells are surrounded by a rough, rigid cell wall that represents 20-25% of the dry weight of the cells (9). The cell wall of *C. albicans* and *S. cerevisiae* consists of about 85-90% polysaccharide, 10-15% protein, 20 and a small amount of lipids (19, 20). The polysaccharide components consist of mannan, glucan, and a small amount of chitin. Most of the proteins are covalently linked to the mannan (mannoprotein), which is located in the outermost layer of the cell wall. A fraction of the proteins 25 is also covalently linked to glucan (8). The proportions of these different components vary with the species, but in *S. cerevisiae* there are approximately equal proportions of mannan and glucan, and about equal amounts of alkali-soluble glucan and alkali-insoluble glucan (3).

30 The glucan microfibriles are located mostly in the inner part of the cell wall. The high mannose content present in *C. albicans* cell wall is absent in *C. neoformans*, and glucose is the major monosaccharide constituent of the cryptococcal cell wall. The cell wall of uncapsulated *C.*

35 *neoformans* is composed mainly of glucan.

$\beta(1-3)$ -glucans are unique for all medically important fungi and are shed during growth (16). Thus, determination of $\beta(1-3)$ -glucans appear to be a useful marker in the laboratory diagnosis of deep fungal infections.

5 The analysis of $\beta(1-3)$ -glucans is based on the binding of the polysaccharide to the coagulation factor G. This glucan test, however, has some limitations. It does not react exclusively with $\beta(1-3)$ glucans, since also (1-3)(1-4)- α -D-glucan (negaran) and (1-2)(1-3)(1-6)- α -D-
10 glucan (yeast α -D-mannan), and (1-6)- β -D-glucan (gyrophoran) may activate the G factor (18). The reactivity of factor G is also dependent on the molecular weight, conformation and degree of branching of the glucans (18). Moreover, there are some contradictions regarding its ef-
15 fectiveness of determining glucans in *Cryptococcus neoformans* infections (17).

Compounds with a high binding specificity for $\beta(1-3)$ -glucans would be useful tools for providing an analysis of $\beta(1-3)$ -glucans in any body fluid, such as blood,
20 urine, or in biopsy specimens of patients with suspected fungal infections, and consequently for providing a laboratory diagnosis of fungal infection.

Summary of the invention

25 The object of the present invention is to provide antibodies reactive with $\beta(1-3)$ -glucans as present in free form, in cell wall fragments, and in intact fungal cells with a high specificity for use in the laboratory diagnosis of fungal infections.

30 According to a first aspect of the present invention, a monoclonal antibody reactive with $\beta(1-3)$ -glucans is provided. Said antibody is reactive with $\beta(1-3)$ - and/or $\beta(1-3)(1-6)$ -glucan associated epitopes in free, non-associated form, in cell wall fragments and/or on an
35 intact cell surface. Said antibody is B3B or A10A.

According to a second aspect of the invention, the use of said antibody for the diagnosis of fungal infec-

tions is provided. Further, said antibody may be used for the detection of medically important fungi, e.g. mould, in air, water, dust or other components.

According to a third aspect of the invention, a diagnostic kit for the diagnosis of fungal infections comprising said monoclonal antibody is provided.

According to a fourth aspect of the present invention, a method for diagnosing fungal infections comprising said monoclonal antibody is provided. Additionally, a method for detecting medically important fungi, e.g. mould, is provided.

Brief description of the drawings

Figure 1 shows the antibody activities of A10A and B3B to $\beta(1-3)(1-6)$ -glucan, $\beta(1-3)$ -glucan, $\beta(1-3)(1-4)$ -glucan, $\beta(1-6)$ -glucan, *Candida albicans* cell wall fragments (CaCW), and *Cryptococcus neoformans* cell wall fragment (CnCW) as analyzed by ELISA at a dilution of 1/10. The antibody activity is expressed as the absorbance value.

Detailed description of the invention

As stated above, the cell wall of all medically important fungi contains a unique polyglucose compound, a $\beta(1-3)$ -glucan. $\beta(1-3)$ -glucans refer to polysackarides having the basic unit $\beta(1-3)$. These glucans may be $\beta(1-3)$ -glucans without side chains, or may be branched to various degrees having $\beta(1-6)$ side chains, $\beta(1-3)(1-6)$ -glucans. The side chains may be varied with respect to the number of $\beta(1-6)$ per $\beta(1-3)$, the length of $\beta(1-6)$ branched $\beta(1-3)$ etc.

Murine monoclonal antibodies were produced against linear $\beta(1-3)$ -glucans and $\beta(1-6)$ -branched $\beta(1-3)$ -glucans (also called $\beta(1-3)(1-6)$ -glucan) and their specificity was characterized. The antibodies were analysed for reactivity to other β -glucans, fungal cell wall fragments, and intact fungal cells.

Two monoclonal antibodies, A10A and B3B, reactive with $\beta(1-3)$ -glucan and $\beta(1-3)(1-6)$ -glucan in ELISA, recognized immunoreactive epitopes in *Candida albicans* and non-encapsulated *Cryptococcus neoformans* cell wall fragments (CaCW, CnCW) (fig 1). The A10A epitope was present in both $\beta(1-3)$ -glucan and $\beta(1-6)$ -glucan. The B3B epitope included $\beta(1-3)$ -glucan, but most probably not $\beta(1-6)$ -glucan. Thus, B3B appeared to recognize the $\beta(1-3)$ -linkage, present in $\beta(1-3)$ -glucan and $\beta(1-3)(1-6)$ -glucan, while A10A reacts with glucan consisting of both types of linkages, i.e. reacts with $\beta(1-3)$ -glucans, $\beta(1-6)$ -glucans and $\beta(1-3)(1-6)$ -glucans.

By indirect immunofluorescence only A10A recognized a $\beta(1-3)(1-6)$ associated epitope on the intact cell surface of *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata*, and *C. neoformans*.

In summary, B3B demonstrated the presence of immunoreactive epitopes, i.e. $\beta(1-3)$ -glucan and $\beta(1-3)(1-6)$ -glucan, in cell wall fragments of *C. albicans* and *C. neoformans* (fig 1), as well as in free form $\beta(1-3)$ - and $\beta(1-3)(1-6)$ -glucans (table 2), while A10A in addition recognized a $\beta(1-3)(1-6)$ -glucan associated epitope that was readily available on the surface of whole cells of *C. neoformans* and all *Candida* species tested.

Thus, the two monoclonal antibodies to $\beta(1-3)$ -glucans, A10A and B3B, could be used in combination (although not excluding also separately) in an immunoassay for the detection of free, cellwall associated or cell surface associated $\beta(1-3)$ -glucans. Thereby, they are of help in laboratory diagnosis of fungal infections, in particular deep fungal infections, but also superficial infections, such as *Candida* vaginitis or mucocutane candidiasis.

Thus, in the research work leading to the present invention murine monoclonal antibodies directed against $\beta(1-6)$ -branched $\beta(1-3)$ -glucans were characterized by ELISA with respect to crossreactions with $\beta(1-3)$ -, $\beta(1-$

6)-, $\beta(1-4)(1-3)$ -glucans, *C. albicans* and *C. neoformans* cell wall fragments. The presence of a β glucan epitope on the surface of the cell wall of *C. albicans*, *C. parapsilosis*, *C. glabrata*, *C. krusei*, an uncapsulated mutant of *C. neoformans* was investigated by immunofluorescence microscopy.

We present what to our knowledge is the first mAb (A10A) that reacts with a $\beta(1-3)(1-6)$ -glucan epitope on the intact cell surface of *Candida*.

10 By a $\beta(1-3)$ -glucan associated epitope is meant an epitope which is present in $\beta(1-3)$ -glucans, and $\beta(1-3)(1-6)$ -glucans.

By a $\beta(1-3)(1-6)$ -glucan associated epitope is meant an epitope which is present in $\beta(1-3)$ -glucans, $\beta(1-6)$ -glucans, and $\beta(1-3)(1-6)$ -glucans.

Materials and Methods

Strains and condition of growth

C. albicans ATCC 64549, *C. glabrata* ATCC 90030, *C. parapsilosis* CCUG 37233, *C. krusei* ATCC 6258, and an uncapsulated *C. neoformans* strain 602 were cultivated in Sabouraud dextrose broth, at 37°C overnight. The conversion of yeast to germ tube and hyphal forms of *C. albicans* was carried out by transferring the *C. albicans* yeast cells to RPMI 1640 and cultivation at 37°C for 18h.

Antigens

Cell wall fragments

Cell wall fragments of *C. albicans* (CaCW) and *C. neoformans* strain 602 (CnCW) were prepared by treatment of the yeast cells by glass beads as described earlier (12). The glucan structure in CaCW is composed of branching $\beta(1-3)(1-6)$ linkages. The cell wall of uncapsulated *C. neoformans* is composed mainly of $\alpha(1-3)(1-4)$ D and $\beta(1-3)(1-6)$ -glucans (6).

Glucans

Glucan from *Saccharomyces cerevisiae* with $\beta(1-6)$ -branched $\beta(1-3)$ -linked glucose residues [$\beta(1-3)(1-6)\text{glu}$], *Alcaligenes faecalis* curdlan with $(1-3)$ - β -linkages [$\beta(1-3)$], and glucan from barley with $(1-4)(1-3)$ - β -linkages [$\beta(1-4)(1-3)$] were purchased from Sigma (St Louis, USA). Pustulan from lichen *Umbilicaria papullosa* with $(1-6)$ - β -linked glucose residues [$\beta(1-6)$] was purchased from Calbiochem (San Diego, USA). According to the manufacturer pustulan contained only glucose. The purity of the glucans of baker yeast, curdlan, and barley were 98, 99 and 96% respectively, according to the specifications. Table 1 summarizes the trivial names, physical properties, and sources of the β -glucans used in this study. $\beta(1-3)(1-6)\text{glu}$, $\beta(1-4)(1-3)$, and $\beta(1-3)$ were dissolved in 0.3M NaOH at a concentration of 20 mg/ml. $\beta(1-6)$ was dissolved in water at 100°C at a concentration of 20 mg/ml.

Table 1

20 **Structural and physical properties of β -glucans used in this study**

Trivial name	Type of linkages	Source	Molecular weight	Solubility in water	Linear/branched
Yeast glucan	$\beta(1-3)(1-6)$ -D-	<i>Saccharomyces cerevisiae</i>	17,000	insoluble	branched
Curdlan	$\beta(1-3)$ -D-	<i>Alcaligenes faecalis</i>	294,000	insoluble	linear
Barley	$\beta(1-4)(1-3)$ -D-	Barley plant	23,000	insoluble	linear
Pustulan	$\beta(1-6)$ -D-	<i>Umbilicaria papullosa</i>	20,000	soluble	linear

Antibodies to β -glucan

Production of mAbs

For the production of mAbs female Balb/c mice (6-8 weeks old) were immunized intraperitoneally (i.p) with

either 50 μ g of $\beta(1-3)$ (2 mice), $\beta(1-3)(1-6)$ glu (4 mice) or 2.5×10^7 cells of formaldehyde treated uncapsulated *C. neoformans* (4 mice) suspended in 200 μ l PBS containing 1 μ g of cholera toxin, which was used as an adjuvant (23).
5 Two and four weeks later, the mice received intraperitoneal injections with the same amount of antigen. One week after the last injection, blood was collected and the antibody response to $\beta(1-3)(1-6)$ glu analyzed by ELISA. After an additional week another injection with the same
10 amount of antigen was given, and three to four days later the animals were killed and their spleens used for fusion.

Myeloma cells were cultured in Iscoves medium supplemented with 2mM L-glutamine, penicillin (100 U/ml),
15 streptomycin (100 μ g/ μ l) and 1% (w/v) fetal bovine serum (growing medium). Cell fusion and selection of hybrids were carried out as described by Köhler and milstein (11). Spleen lymphocytes from immunized mice were fused with SP2/0 murine myeloma cells at a 5:1 ratio using PEG
20 1500 (Boehringer Mannheim GmbH, Mannheim, Germany) as the fusing agent. The fused cells were distributed in 96-well culture plates at an approximately density of 4×10^5 cells in 200 μ l HAT selection medium (growing medium supplemented with hypoxanthin, aminopterin, thymidine). On
25 day 10 post-fusion, the culture supernatants were screened for the presence of antibodies specific to $\beta(1-3)(1-6)$ glu and $\beta(1-3)$ by ELISA. Positive hybridomas, which all were of IgM isotype as determined by ELISA, were cloned by limiting dilution on a feeder layer of
30 Balb/c peritoneal macrophages. Cells were grown in HAT medium for two weeks. The HAT was substituted by HT medium (growing medium supplemented with hypoxanthin and thymidine). Positive clones were cultivated in serum free medium HyQ-CCM1 (from Hyclone Laboratories Inc, Utah,
35 USA).

MAbs were purified by $(\text{NH}_4)_2\text{SO}_4$ precipitation followed by affinity chromatography on agarose gel with co-

valently linked IgG goat anti-mouse IgM (Sigma, St Louis, USA). The fraction was dialyzed against PBS overnight at 4°C. The protein concentration was determined by Coomassie protein assay reagent kit (Pierce, IL; USA).

- 5 The protein concentration was adjusted to 100 µg/ml in 1% BSA in PBS and stored -70°C.

ELISA

- Microplate wells (Nunc immunoplate, Denmark) were
10 coated with 100 µl of a 50 µg/ml solution of β(1-3), β(1-4)(1-3), β(1-6), CaCW or CnCW and a 20µg/ml of β(1-3)(1-6)glu solution containing 50 mM Na₂CO₃ buffer, pH 9.3. The plates were incubated at room temperature (r.t.) for two hours and thereafter kept at 4°C overnight. After rinsing
15 the plate once with PBS, 100µl of blocking buffer (BF) (1% BSA in PBS) were added to each well and the plate incubated for 1h at r.t. The plate was rinsed once with PBS. mAbs diluted in 1/10, 1/50, 1/100 and 1/1000 in PBS, were added to each well (100µl) and incubated for two hr
20 at r.t. Hereafter the plate was rinsed three times with 0.05% Tween-20 in PBS (PBS-T) between each incubation step. Biotinylated rabbit anti-mouse IgM (DAKO, Glostrup, Denmark) diluted 1/5000 in PBS-T was added to the wells (100 µl). The plate with monoclonal antibodies was further
25 incubated at r.t. for 2h, and thereafter 100 µl of alkaline phosphatase conjugated extravidin (Sigma, St Louis, USA) diluted 1/1000 in PBS-T were added and the plate was incubated at r.t. for 60 min. Para-nitrophenylphosphate (1mg/ml, Sigma, St Louis, USA) diluted in diethanolamine buffer (pH 9.8) was added to each
30 well and the absorbance was read at 405 nm when a suitable color had developed.

Inhibition-ELISA

- 35 Increasing amounts of β(1-3)(1-6)glu, β(1-3), β(1-4)(1-3), β(1-6), CaCW, CnCW (1-1000 µg/ml) were added to series of tubes containing a constant amount of mAb or

rabbit serum. The mAbs were also incubated with monosaccharide; β -D-glucose, glucose amine and mannose or disaccharides; trehalose with α (1-1), maltose with α (1-4) and cellobiose with β (1-4) linkages at the concentration of 50 and 1000 μ g/ml. The mAb solutions were incubated at r.t. for 30 min and kept at 4°C overnight. The solutions were centrifuged to remove any precipitates, and the supernatants were analyzed for the remaining antibody activity against CaCW or β (1-3)(1-6)glu, as antigens. The mAb A10A and B3B were diluted 1/50 and 1/20 respectively, in PBS supplemented with 0.1% BSA for the inhibition assay. The inhibition capacity of an antigen was defined as the concentration needed for inhibiting the antibody activity to 50%, i.e. reducing the absorbance to 50% of that of the unabsorbed serum dilution (EI_{50}) (14).

Immunofluorescence microscopy (IF)

The immunofluorescence assay was carried out as described by Casanova et.al. with some modifications (2). Microorganisms were washed 3 times in PBS, the concentration of the cells were adjusted to 10^6 cells/ml in PBS and drops of the cell suspensions were placed on microscope slides and allowed to air dry. The microorganisms were fixed for 20 min with 0.2% formaldehyde in PBS. The microscope slides were washed in 3 changes of PBS for a total of 15 min. MAbs (20 μ l) diluted 1/20 in PBS, were added to the slides and were incubated at r.t. for 60 min in a moisture chamber. The slides were washed as described above. Biotin conjugated rabbit anti-mouse IgM (DAKO, Glostrup, Denmark) diluted 1/100 in PBS was added and slides were incubated at r.t for another 60 min. FITC-conjugated avidin (Sigma, St Louis, USA) diluted 1/200 in PBS was added (20 μ l) to the slides and were incubated at r.t. for 30 min in a moisture chamber. The slides were washed as above and rinsed with distilled water, and mounted with Kaiser's glycerol gelatin (Merck, Darmstadt,

Germany). The cells were examined with a Zeiss photomicroscope equipped with fluorescence.

Examples

5 Example 1

Specificity of mAbs against $\beta(1-3)$ -glucans

MABs were screened against $\beta(1-3)(1-6)$ glu and $\beta(1-3)$. Only mABs of IgM class were found. Out of four selected mABs two were further analyzed. The reactivity of
10 A10A and B3B against $\beta(1-3)(1-6)$ glu and $\beta(1-3)$, $\beta(1-4)(1-3)$, $\beta(1-6)$, CnCW, and CaCW were studied (Fig. 1). A10A showed a high antibody activity against all antigens except for $\beta(1-6)$, and $\beta(1-4)(1-3)$. B3B showed an overall lower activity against the antigens. The highest antibody
15 activity was obtained against CaCW followed by CnCW. It was intermediate against $\beta(1-3)$ and low against $\beta(1-3)(1-6)$ glu, while it was not active against $\beta(1-6)$ and $\beta(1-4)(1-3)$. The highest antibody activity for both mABs was found against CaCW. In addition, A10A showed a high ac-
20 tivity against $\beta(1-3)(1-6)$ glu.

The cross-reaction between $\beta(1-3)(1-6)$ glu or CaCW and the various glucan antigens were studied by inhibition-ELISA.

It was found that the EI_{50} of A10A for the homologous
25 antigen, $\beta(1-3)(1-6)$ glu, and CnCW were almost identical (6 and 5 μ g/ml, respectively) (Table 1). EI_{50} for $\beta(1-3)$ and $\beta(1-6)$ was 7- fold higher. EI_{50} for $\beta(1-4)(1-3)$ and CaCW was more than 60 and 40 times higher respectively, than the $\beta(1-3)(1-6)$ glu or CnCW.

Table 1

Inhibition of the anti- $\beta(1-3)(1-6)$ glu and CaCW antibody activities of A10A by absorption with $\beta(1-3)(1-6)$ glu, $\beta(1-3)$, $\beta(1-4)(1-3)$, $\beta(1-6)$, CaCW, and CnCW. A10A was diluted 1/50

Absorbing agent	EI ₅₀ (μ g/ml) \pm Standard deviation	
	$\beta(1-3)(1-6)$ glu [#]	CaCW
$\beta(1-3)(1-6)$ glu	6 \pm 2	31 \pm 12
$\beta(1-3)$	40 \pm 12	185 \pm 170
$\beta(1-4)(1-3)$	359 \pm 39	>*
$\beta(1-6)$	43 \pm 17	>*
CaCW	238 \pm 112	56 \pm 6
CnCW	5 \pm 2	6 \pm 4

5 #The absorbance value of the unabsorbed antibody was 1.8 against $\beta(1-3)(1-6)$ glu and 1.2 against CaCW.

* No inhibition at the highest concentration tested, 1000 μ g/ml.

10 The A10A activity against CaCW showed that CnCW was a 9-fold stronger inhibitor than the homologous antigen (Table 1). In addition, $\beta(1-3)(1-6)$ glu was also stronger as inhibitor than CaCW. EI₅₀ for CaCW was almost twofold higher (56 μ g/ml) than that of $\beta(1-3)(1-6)$ glu (31 μ g/ml). Thus, the A10A epitope involved the branching region of the glucan, the $\beta(1-3)(1-6)$ linkage, which was available to a higher extent in CnCW than in CaCW.

15 The specificity of B3B to CaCW was analyzed by inhibition-ELISA. The EI₅₀ for CaCW and $\beta(1-3)$ was roughly the same and they were more than 15 times higher than that of EI₅₀ for $\beta(1-3)(1-6)$ glu (Table 2). $\beta(1-4)(1-3)$ and CnCW did not inhibit the anti-CaCW antibody activity at the highest concentration tested. The EI₅₀ for $\beta(1-6)$ was almost 40-fold higher than that of $\beta(1-3)(1-6)$ glu. This inhibition pattern of B3B differed from that of A10A by the lack of inhibitory effect of CnCW, while still being inhibited by $\beta(1-3)(1-6)$ glu. Thus, the B3B epitope was

highly exposed by the free form of $\beta(1-3)(1-6)$. None of the mono- and disaccharides inhibited the anti- $\beta(1-3)(1-6)$ glu antibody activity of the two mAbs.

5

Table 2

Inhibition of the B3B anti- CaCW antibody activity by absorption with $\beta(1-3)(1-6)$ glu, $\beta(1-3)$, $\beta(1-4)(1-3)$, $\beta(1-6)$, CaCW, and CnCW. The mAb was diluted 1/20 in in PBS containing 0.1% BSA. The absorbance value was 0.4 of the unabsorbed antibody.

Absorbing agent	BI ₅₀ (μ g/ml)
$\beta(1-3)(1-6)$ glu	20
$\beta(1-3)$	450
$\beta(1-4)(1-3)$	>*
$\beta(1-6)$	750
CaCW	306
CnCW	>*

10 *> , no inhibition at the highest concentration tested (1000 μ g/ml).

Example 2**Availability of $\beta(1-3)(1-6)$ epitopes on the cell surface of *Candida* and *C. neoformans***

15 The availability of $\beta(1-3)(1-6)$ -glucan for antibody binding on the cell surface of various *Candida* species and *C. neoformans* were analyzed by IF microscopy using A10A and B3B. Yeast and mycelial forms of *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and the uncapsulated
20 mutant of *C. neoformans* were all positive by IF (Fig. 3). The intensity of fluorescence differed depending on the morphology and distribution of the antigens in the cell wall. Uncapsulated *C. neoformans* was strongly immunoreactive with A10A. This mAb also stained the yeast and myce-
25 lial forms of *C. albicans*, but somewhat weaker. The other species of *Candida*, *C. parapsilosis*, *C. krusei* and *C. glabrata* were all stained with A10A.

B3B did not stain any of the fungal strains.

Discussion

While A10A reacted with an epitope exposed on the cell surface of intact fungal cells, the other one recognized an epitope present in the cell wall fragments only.

5 Both mAbs reacted with the free form $\beta(1-3)$ or $\beta(1-3)(1-6)$ -glucan. The mycelial form of *C.albicans* was stained with A10A to the same degree as the yeast form as shown by IF.

The novel A10A mAb also recognized an epitope present in $\beta(1-6)$. MAbs directed against $\beta(1-6)$ and $\beta(1-3)(1-6)$ -glucans have been described earlier (4, 22). The mAb directed against $\beta(1-6)$ as obtained by immunization with Zymolyase extract from *C.albicans* was shown not to react with epitopes on the cell wall of *C.albicans* unless
15 the outer layer, being formed by mannoproteins, was disrupted by the effect of tunicamycin. Tunicamycin interferes with the N-glycosylation of proteins so that new synthesis of mannoproteins will not become glycosylated during cell growth (10). Thus, A10A as well as B3B differed from this $\beta(1-6)$ epitope binding monoclonal. Regarding the other two reported mAbs, one was suggested to be mainly directed against $\beta(1-3)$ in Schizophyllan ($\beta(1-3)$ -glucan with branching $\beta(1-6)$ glucose residues) (5), while the detailed specificity of the other one with regard to various glucans was not reported. The presence of those epitopes on the cell surface of fungi was, however, not studied. The mAbs were produced for measuring either schizophyllan in serum during treatment by this agent as an anti-cancer drug, or for determining the immunological
30 properties of another anti-tumor polysaccharide containing $\beta(1-3)$ and $\beta(1-6)$ -glucans (5). Thus, in two of the first described monoclonals none was analysed for binding activities against native $\beta(1-3)$ glucans exposed in the cell wall fragments of *Candida* or *Cryptococcus* as was
35 shown for A10A and B3B. In order to perform analyses on natural components such as intact cells, cell wall frag-

ments, or shed $\beta(1-3)$ glucans, only our mabs are characterized with respect to this.

Our second mAb B3B did not recognize cell wall antigens in indirect IF and only weakly in inhibition-ELISA. Most probably the explanation for this is the presence of the epitope mainly in the deeper parts of the cell wall and thereby not available on the cell surface of the intact cell. Yet another explanation could be that it only recognizes a particular form of the glucan antigen, since the weak anti-CaCW activity of B3B was inhibited by $\beta(1-3)(1-6)$ -glucan at a low concentration. Although B3B was produced against $\beta(1-3)$, the EI_{50} for this glucan regarding B3B anti-CaCW activity was approximately 15 times higher than that of $\beta(1-3)(1-6)$. The fact that $\beta(1-3)$ is linear and $\beta(1-3)(1-6)$ is branched in addition to a 10 times higher molecular weight than $\beta(1-3)(1-6)$ may have influenced the epitope density. It is also known that the ultrastructure of higher molecular weight β glucans exhibits various forms such as single-helical, triple-helical, and a mixture of both, due to interchain hydrogen bonding between each main chain of polyglucose residues (25). Lower molecular weight β glucans adopt a randomly coiled form in aqueous solution (1). The percentage of branching, i.e. the number of (1-6)- per (1-3)-linkage may also differ between different fungal species. The availability of epitopes may be higher in randomly coiled regions of branched β glucans.

During growth medically important fungi seem to shed $\beta(1-3)$ -glucan into the culture medium. The concentration of $\beta(1-3)$ -glucan in serum from patients with deep fungal infections can be very high as determined by the G factor based *Limulus* assay (16, 17, 21). We have found $\beta(1-3)$ -glucan in serum of all patients with candidemia, but in none of women with superficial *Candida* infection, or healthy controls (13). Thus, $\beta(1-3)$ -glucan seems to be a sensitive assay. However, since also other types of glucans may activate the *Limulus* assay (24b) an immunoassay

based on two specific antibodies would be more specific. Two assays have been reported for the determination of $\beta(1-3)$ glucan levels: the first utilizes a monoclonal IgG antibody specific for consecutive alignments of $\beta(1-3)$ -D-glucopyranosyl residues and biotinylated horseshoe crab protein, T-GBP, from *Tachypleus tridentatus* (24), while the second assay employs a high affinity receptor (galactosyl ceramide) for $\beta(1-3)$ glucans and a mAb that is described as being specific for complex fungal cell wall $\beta(1-3)$ glucans (15). The T-GBP-protein - based sandwich ELISA was shown to react readily with $\beta(1-3)$ glucans including barley $\beta(1-4)(1-3)$ (24). The other immunoassay, based on the capture agent galactosyl ceramide, was shown to not react with $\beta(1-3)$ glucan, a glucan which readily reacts with our mAbs. Furthermore in that report no analyses were performed with *Candida* or *Cryptococcus* whole cells or cell wall fragments.

The presence of $\beta(1-3)$ -glucans in serum of patients with deep fungal infections may be a useful marker for laboratory diagnosis of these infections. Future investigations will address the usefulness of our mAbs to glucan in an immunoassay-based kit for the rapid detection of $\beta(1-3)$ glucans in blood samples, in other specimens from patients with invasive fungal infections, or in other body fluids such as mucosal secretions and urine. Moreover, the presence of the $\beta(1-3)$ or $\beta(1-3)(1-6)$ glucan epitope on the intact surfaces of both *Candida* species and non-encapsulated *C. neoformans*, as seen with A10A, or in cell wall fragments as seen with both A10A and B3B has not been reported earlier regarding activities of monoclonal antibodies directed against $\beta(1-3)$ glucans.

The antibodies according to the invention can be used for the detection of free, cellwall associated-, and/or cell surface-associated $\beta(1-3)$ glucans utilizing immunoassays or immunohistology for the laboratory diagnosis of fungal infections. Further, they may be used in immunotherapy.

The antibodies disclosed in the present application may also be used for the detection of airborne mould, or mould present in dust or water, or in any other component. Thus, the antibodies according to the invention may
5 be used for the detection of all kinds of medically important fungi, for example in connection to allergy problems and in the detection of house mould.

References

1. Adachi, Y., N. Ohno, T. Yadomae, Y. Suzuki, M. Oh-
sawa, and S. Oikawa. 1990. Thermal denaturation of
5 1-3-beta -D glucans in neutral aqueous solution
above 130 degree effect on physicochemical proper-
ties. Carbohydr Res 198:111-122.
2. Casanova, M., M. L. Gil, L. Cardenoso, J. P. Marti-
nez, and R. Sentandreu. 1989. Identification of
10 wall-specific antigens synthesized during germ tube
formation by Candida albicans. Infect Immun 57:262-
71.
- 3 Fleet, G. H., and D. J. Manners. 1976. Isolation and
composition of an alkali-soluble glucan from the
15 cell walls of Saccharomyces cerevisiae. J Gen Micro-
biol 94:180-92.
- 4 Hirata, A., Y. Adachi, W. Itoh, M. Komoda, K. Ta-
bata, and I. Sugawara. 1994. Monoclonal antibody to
proteoglycan derived from Grifola frondosa (Mai-
take). Biol Pharm Bull 17:539-42.
- 20 5. Hirata, A., M. Komoda, W. Itoh, K. Tabata, S. Ito-
yama, and I. Sugawara. 1994. An improved sandwich
ELISA method for the determination of immunoreactive
schizophyllan (SPG). Biol Pharm Bull 17:1437-40.
- 25 6. James, P. G., R. Cherniak, R. G. Jones, C. A.
Stortz, and E. Reiss. 1990. Cell-wall glucans of
Cryptococcus neoformans Cap 67. Carbohydr Res
198:23-38.
7. Jones, J. M. 1990. Laboratory diagnosis of invasive
30 candidiasis. Clin Microbiol Rev 3:32-45.
8. Kapteyn, J. C., L. L. Hoyer, J. E. Hecht, W. H. Mul-
ler, A. Andel, A. J. Verkleij, M. Makarow, H. Van
Den Ende, and F. M. Klis. 2000. The cell wall archi-
tecture of Candida albicans wild-type cells and cell
35 wall-defective mutants. Mol Microbiol 35:601-11.

9. **Klis, F. M.** 1994. Review: cell wall assembly in yeast. *Yeast* 10:851-69.
10. **Koch, Y., and K. H. Rademacher.** 1980. Chemical and enzymatic changes in the cell walls of *Candida albicans* and *Saccharomyces cerevisiae* by scanning electron microscopy. *Can J Microbiol* 26:965-70.
11. **Kohler, G., and C. Milstein.** 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256:495-7.
12. **Kondori, N., L. Edebo, and I. Mattsby-Baltzer.** 2002. *Candida albicans* cell wall antigens for serological diagnosis of candidemia. *Medical Mycology* in press.
13. **Kondori, N., L. Edebo, and I. Mattsby-Baltzer.** 2002. Circulating B(1-3)-glucan and IgG subclass antibodies to *C. albicans* cell wall antigens in patients with systemic candidiasis. Submitted.
14. **Mattsby-Baltzer, I., Z. Mielniczuk, L. Larsson, K. Lindgren, and S. Goodwin.** 1992. Lipid A in *Helicobacter pylori*. *Infect Immun* 60:4383-7.
15. **Milton, D. K., K. U. Alwis, L. Fisette, and M. Muilenberg.** 2001. Enzyme-linked immunosorbent assay specific for (1-->6) branched, (1-->3)-beta-D-glucan detection in environmental samples. *Appl Environ Microbiol* 67:5420-4.
16. **Miyazaki, T., S. Kohno, K. Mitsutake, S. Maesaki, K. Tanaka, and K. Hara.** 1995. (1-->3)-beta-D-glucan in culture fluid of fungi activates factor G, a limulus coagulation factor. *J Clin Lab Anal* 9:334-9.
17. **Miyazaki, T., S. Kohno, K. Mitsutake, S. Maesaki, K. Tanaka, N. Ishikawa, and K. Hara.** 1995. Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. *J Clin Microbiol* 33:3115-8.
18. **Nagi, N., N. Ohno, Y. Adachi, J. Aketagawa, H. Tamura, Y. Shibata, S. Tanaka, and T. Yadomae.** 1993. Application of limulus test (G pathway) for the de-

tection of different conformers of (1-->3)-beta-D-glucans. Biol Pharm Bull 16:822-8.

19. Nelson, R. D., N. Shibata, R. P. Podzorski, and M. J. Herron. 1991. Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action. Clin Microbiol Rev 4:1-19.
20. Nguyen, T. H., G. H. Fleet, and P. L. Rogers. 1998. Composition of the cell walls of several yeast species. Appl Microbiol Biotechnol 50:206-12.
21. Obayashi, T., M. Yoshida, T. Mori, H. Goto, A. Yasuoka, H. Iwasaki, H. Teshima, S. Kohno, A. Horiuchi, A. Ito, and et al. 1995. Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20.
22. Sanjuan, R., J. Zueco, R. Stock, J. Font de Mora, and R. Sentandreu. 1995. Identification of glucan-mannoprotein complexes in the cell wall of Candida albicans using a monoclonal antibody that reacts with a (1,6)-beta-glucan epitope. Microbiology 141 (Pt 7):1545-51.
23. Sverremark, E., and C. Fernandez. 1997. Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512. Immunology 92:153-9.
24. Tamura, H., S. Tanaka, T. Ikeda, T. Obayashi, and Y. Hashimoto. 1997. Plasma (1-->3)-beta-D-glucan assay and immunohistochemical staining of (1-->3)-beta-D-glucan in the fungal cell walls using a novel horse-shoe crab protein (T-GBP) that specifically binds to (1-->3)-beta-D-glucan. J Clin Lab Anal 11:104-9.
25. Williams, D. L. 1993. Beta glucans structure and biological function.

20

CLAIMS

1. A monoclonal antibody reactive with a $\beta(1-3)$ -glucan associated epitope.
2. A monoclonal antibody according to claim 1,
5 wherein said antibody is reactive with a $\beta(1-3)$ -glucan associated epitope in free, non-associated form.
3. A monoclonal antibody according to claim 1, wherein said antibody is reactive with a $\beta(1-3)$ -glucan associated epitope in cell wall fragments.
- 10 4. A monoclonal antibody according to claim 3, wherein said $\beta(1-3)$ -glucan associated epitope is available in cell wall fragments of *C. albicans* and/or *C. neoformans*.
5. A monoclonal antibody according to any one of the
15 claims 1-4, wherein said antibody is B3B.
6. A monoclonal antibody according to claim 1, wherein said antibody is reactive with a $\beta(1-3)(1-6)$ -glucan associated epitope.
7. A monoclonal antibody according to claim 6,
20 wherein said antibody is reactive with a $\beta(1-3)(1-6)$ -glucan associated epitope in free, non-associated form.
8. A monoclonal antibody according to claim 6, wherein said antibody is reactive with a $\beta(1-3)(1-6)$ -glucan associated epitope in cell wall fragments.
- 25 9. A monoclonal antibody according to claim 8, wherein said $\beta(1-3)(1-6)$ -glucan associated epitope is available in cell wall fragments of *C. albicans* and/or *C. neoformans*.
10. A monoclonal antibody according to any one of
30 the claims 1-9, wherein said antibody is A10A.
11. A monoclonal antibody according to claim 1, wherein said antibody is reactive with a $\beta(1-3)$ -glucan associated epitope available on an intact cell surface.
12. A monoclonal antibody according to claim 11,
35 wherein said $\beta(1-3)$ -glucan associated epitope is available on the cell surface of *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and/or *C. neoformans*.

13. A monoclonal antibody according to claim 6, wherein said antibody is reactive with a $\beta(1-3)(1-6)$ -glucan associated epitope available on an intact cell surface.

5 14. A monoclonal antibody according to claim 13, wherein said $\beta(1-3)(1-6)$ -glucan associated epitope is available on the cell surface of *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and/or *C. neoformans*.

10 15. A monoclonal antibody according to any one of the claims 11-14, wherein said antibody is A10A.

16. Use of at least one antibody according to any one of the claims 1-15 for the diagnosis of fungal infections.

15 17. Use of at least one antibody according to any one of the claims 1-15 for the detection of mould in air, water, dust or other components.

18. Diagnostic kit for the diagnosis of fungal infections comprising a monoclonal antibody according to any one of the claims 1-15.

20 19. Method for diagnosing fungal infections comprising performing an assay for the detection of $\beta(1-3)$ -glucans in a sample using a monoclonal antibody according to any one of the claims 1-15, wherein the presence of $\beta(1-3)$ -glucans indicates a fungal infection in said
25 patient.

20. Method for detecting mould comprising performing an assay for the detection of $\beta(1-3)$ -glucans in a sample using a monoclonal antibody according to any one of the claims 1-15, wherein the presence of $\beta(1-3)$ -glucans
30 indicates the presence of mould.

1/1




Figure 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01638

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: G01N 33/569, A61K 39/395, C07K 16/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: G01N, A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Applied and Environmental Microbiology, Vol. 67, No. 12, 2001, Donald K. Milton et al, "Enzyme-Linked Immunosorbent Assay Specific for (1-6) Branched, (1-3)-Beta-D-Glucan Detection in Environmental Samples", pages 5420-5424, abstract, page 5422 --	1-20
X	Biol. Pharm. Bull, Vol. 17, No. 11, 1994, Akio Hirata et al, "An Improved Sandwich ELISA Method for the Determination of Immunoreactive Schizophyllan (SPG), pages 1437-1440, abstract, page 1437, column 1, lines 1-12, discussion page 1439 --	1-20

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 December 2003

13 -01- 2004

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

MALIN SÖDERMAN/E1s
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01638

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9931510 A1 (ALPHA-BETA TECHNOLOGY, INC.), 24 June 1999 (24.06.99), abstract, claims 31-33, page 19, lines 19-29 --	1-20
X	Journal of Clinical Laboratory Analysis, Vol. 11, 1997, Hiroshi Tamura et al, "Plasma (1-3)-Beta-D-Glucan Assay and Immunohistochemical Straining of (1-3)-Beta-D-Glucan in the Fungal Cell Walls Using a Novel Horseshoe Crab Protein (T-GBP) The Specifically Binds to (1-3)-Beta-D-Glucan", pages 104-109, abstract --	1-20
X	DATABASE WPI Week 199303 Derwent Publications Ltd., London, GB; Class B04, AN 1993-021305 & JP 4346791 A (TAITO KK), 2 December 1992 (1992-12-02) abstract --	1-20
X	National Library of Medicine (NLM), file Medline, Medline accession no. 8069265, Hirata A. et al: "Monoclonal antibody to proteoglycan derived from Grifola frondosa (Maitake) & Biological & pharmaceutical bulletin, volume 17, no. 4, Apr 1994, pages 539 - 542 --	1-20
X	National Library of Medicine (NLM), file Medline, Medline accession no. 10639364, Onishi J. et al: "Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors", & Antimicrobial agents and chemotherapy. volume 44, no. 2, Feb 2000, pages 368-377 --	1-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01638

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	National Library of Medicine (NLM), file Medline, Medline accession no. 8795207, Douwes J. et al: "Measurement of beta (1--->3)-glucans in occupational and home environments with an inhibition enzyme immunoassay", & Applied and environmental microbiology, vol. 62, no. 9, Sep 1996, pages 3176-3182 --	1-20
A	Biology, vol. 141, 1995, Raquel Sanjuan et al, "Identification of glucan-mannoprotein complexes in the cell wall of Candida albicans using a monoclonal antibody that reacts with a (1,6)-Beta-glucan epitope", pages 1545-1551, abstract -- -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01638

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: **1-20**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

see next sheet

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01638

1.2

Present claims 1-20 relate to a rather broadly defined categories of antibodies defined by reference to a desirable characteristic or property, namely an antibody reactive with $\beta(1-3)$ - and/or $\beta(1-3)(1-6)$ -glucan associated epitopes in "free, non-associated form", in cell wall fragments and/or on an intact cell. The claims cover all antibodies having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such antibodies. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lacks clarity (Article 6 PCT). An attempt is made to define the antibody by reference to a result to be achieved, because the antibody is not well defined. It must be clear from the claims what the antibody binds to. This could be achieved by for example a precise definition of the epitope, a deposition of the antibody or a determination of the 3D-structure of the binding site.

Claims 1-20 do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined, because of the expression "free, non-associated form". It is not clear from the description and the claims what is meant with the expression "free, non-associated form".

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01638

Antibodies reactive with $\beta(1-3)$ - and/or $\beta(1-3)(1-6)$ -glucan associated epitopes in "free, non-associated form", in cell wall fragments and/or on an intact cell are known.

From the description and claims the application therefore is considered to contain two independent inventions, namely:

A first invention according to claims 1-5, 16-20 that has the corresponding "special technical feature" of an antibody reactive with a $\beta(1-3)$ -glucan associated epitope in "free, non-associated" form or in cell wall fragments. The antibody could be called B3B.

A second invention according to claims 1-4, 6-20 that has the corresponding "special technical feature" of an antibody reactive with a $\beta(1-3)$ - and/or $\beta(1-3)(1-6)$ -glucan associated epitope in "free, non-associated form", in cell wall fragments or on an intact cell surface. The antibody could be called A10A.

According to Rule 13.1 and 13.2, an international application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art.

Thus, the invention lacks unity *à posteriori*. The applicant is not invited to pay an additional search fee for the search of invention 2.

INTERNATIONAL SEARCH REPORT
Information on patent family members

31/10/03

International application No.

PCT/SE 03/01638

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
NO	9931510	A1	24/06/99	AU 740158 B	01/11/01
				AU 1396799 A	05/07/99
				CA 2314342 A	24/06/99
				EP 1038180 A	27/09/00
				JP 2002508518 T	19/03/02
				US 6084092 A	04/07/00
				US 6294321 B	25/09/01
				US 6413715 B	02/07/02
				US 2001051717 A	13/12/01
				ZA 9810628 A	24/05/99
